The National Biotechnology Conference is an opportunity to fine-tune your skills, learn new techniques, network with peers, and learn about issues affecting the pharmaceutical science industry. With more than 55 educational sessions, you learn about best practices, success stories, tools, and practical solutions from top speakers from industry, FDA, and academia.
Learn and network with top biotechnology, and bring new ideas back to your lab and office!
More than 50% of attendees are scientists/researchers at the National Biotechnology Conference. Other attendees includes directors, managers, and students focused in the biotech space.
Complimentary organizations can provide valuable resources to scientists who are seeking industry solutions, new emerging trends, and collaboration within the biotech community.
AAPS members primarily come from a pharmaceutics, biopharmaceutics, or pharmacy field of study. AAPS members also represent those scientists from complimentary disciplines, such as chemistry, biology, engineering, and medicine, involved in the discovery, development, and manufacture of pharmaceutical products and therapies.
New and Upcoming Drug Modalities
Regulatory Considerations into the Translational Aspects and Preclinical Evaluation of Immuno-oncology Drugs
Wyss Institute at Harvard University
Development, Current Applications, and Future Utility of the Organ on a Chip Technology
Donald E. Ingber, M.D., Ph.D., is the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. He received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University.
Ingber is a pioneer in the field of biologically inspired engineering, and at the Wyss Institute, he currently leads a multifaceted effort to develop breakthrough bioinspired technologies to advance healthcare and to improve sustainability. His work has led to major advances in mechanobiology, tumor angiogenesis, tissue engineering, systems biology, nanobiotechnology and translational medicine. Through his work, Ingber also has helped to break down boundaries between science, art and design.
Ingber has authored more than 430 publications and 150 patents, founded 5 companies, and has presented 517 plenary presentations and invited lectures world-wide. He is a member of the National Academy of Medicine, National Academy of Inventors, American Institute for Medical and Biological Engineering, and the American Academy of Arts and Sciences. He was named one of the Top 20 Translational Researchers world-wide in 2012 (Nature Biotechnology), a Leading Global Thinker of 2015 (Foreign Policy magazine), and has received numerous other honors in a broad range of disciplines, including the Robert A. Pritzker Award and the Shu Chien Award (Biomedical Engineering Society), the Rous Whipple Award (American Society for Investigative Pathology), the Lifetime Achievement Award (Society of In Vitro Biology), the Leading Edge Award (Society of Toxicology), Founders Award (Biophysical Society) and the Department of Defense Breast Cancer Innovator Award.
Some of Ingber’s most recently developed technologies include an anticoagulant surface coating for medical devices that replaces the need for dangerous blood-thinning drugs; a dialysis-like sepsis therapeutic device that clears blood of pathogens and inflammatory toxins; a shear stress-activated nanotherapeutic that targets clot-busting drugs to sites of vascular occlusion; and Human Organs-on-Chips created with microchip manufacturing methods and lined by living human cells, which are being used to replace animal testing as a more accurate and affordable in vitro platform for drug development and personalized medicine. In 2015, Ingber’s Organs-on-Chips technology was named Design of the Year by the London Design Museum and was also acquired by the Museum of Modern Art (MoMA) in New York City for its permanent design collection. His Organs-on-Chips were also named one of the Top 10 Emerging Technologies of 2016 by the World Economic Forum.